Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Total Debt: 2021-2024

  • Ascendis Pharma A's Total Debt rose 29.77% to $879.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $879.8 million, marking a year-over-year increase of 29.77%. This contributed to the annual value of $891.1 million for FY2024, which is 31.44% up from last year.
  • Ascendis Pharma A's Total Debt amounted to $879.8 million in Q4 2024, which was up 29.77% from $677.9 million recorded in Q4 2023.
  • In the past 5 years, Ascendis Pharma A's Total Debt registered a high of $879.8 million during Q4 2024, and its lowest value of $120.1 million during Q4 2021.
  • Its 3-year average for Total Debt is $655.0 million, with a median of $677.9 million in 2023.
  • Data for Ascendis Pharma A's Total Debt shows a peak YoY soared of 239.19% (in 2022) over the last 5 years.
  • Ascendis Pharma A's Total Debt (Quarterly) stood at $120.1 million in 2021, then soared by 239.19% to $407.3 million in 2022, then spiked by 66.46% to $677.9 million in 2023, then grew by 29.77% to $879.8 million in 2024.
  • Its Total Debt was $879.8 million in Q4 2024, compared to $677.9 million in Q4 2023 and $407.3 million in Q4 2022.